Institute of Cancer Research

Cancer cell
#Breast cancer #Breast Cancer Now #Cancer research #Institute of Cancer Research #Oncology

New discovery could help prevent secondary breast cancer

Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep – forming incurable secondary tumours. Patients with oestrogen receptor positive (ER+) breast cancer – the most common type – have a continued risk of their cancer… Read More

#Cancer Research #News #Trending News

#AstraZeneca #Breast cancer #Institute of Cancer Research #Oncology

EMA approves early-stage breast cancer treatment  

A precision medicine for early-stage breast cancer has been approved by the European Medicines Agency (EMA).   Developed by AstraZeneca and Merck & Co (MSD) under the brand name Lynparza, the treatment is a precision medicine which blocks DNA damage response (DDR) in cells or tumours that have… Read More

#Cancer Research #News

#Business #Institute of Cancer Research

Vesynta moves into London’s latest innovation hub  

Precision medicine start-up Vesynta has become the first medtech company to move into a laboratory at south London’s latest incubator space.   The company, which was spun out from the Adaptive and Responsive Nanomaterials group at University College London, has moved into the Innovation Gateway at The London Cancer… Read More

#News

#DNA #Institute of Cancer Research #Oncology

Junk DNA could lead to cancer, study says  

Non-coding or ‘junk’ DNA could contribute to the development of certain cancers due to how it disrupts the replication of the genome, scientists have discovered.   A team from The Institute of Cancer Research (ICR), London reconstituted the entire process of DNA replication in a test tube in… Read More

#News #Trending News

#Cancer research #Hormone therapy #Institute of Cancer Research

‘Gut bugs’ can drive prostate cancer growth and treatment resistance 

Scientists revealed in a new study how gut bacteria contribute to the progression of advanced prostate cancers and their resistance to hormone therapy by providing an alternative source of growth-promoting androgens, or male hormones.  Hormone therapy is the standard of care for advanced prostate cancer and works… Read More

#Cancer Research #News #Trending News

#Cancer research #Clinical trials #Institute of Cancer Research #Tumour biology

Promise in treatment-resistant advanced ovarian cancer 

A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial, shrinking tumours in half of patients. The combination of drugs, which both work by blocking signals cancer cells need to grow, could offer a new treatment option for women with… Read More

#Cancer Research #News #Trending News

#Cancer research #Clinical trials #Drug development #Drug discovery #Institute of Cancer Research

New cancer drug to enter first clinical trial targeting HSF1 pathway 

The Institute of Cancer Research (ICR), London has discovered an investigational drug called NXP800, which cancer patients are set to receive for the first time. It was discovered in a Phase I clinical trial sponsored by an oncology-focused biopharmaceutical company, Nuvectis Pharma.  The investigational oral drug inhibits the so-called… Read More

#Cancer Research #Trending News

#CAR-T #Drug discovery #Immuno-oncology #Immunotherapy #Institute of Cancer Research

Immune checkpoint inhibitors: What are the risks?

Immuno-oncology has advanced greatly through T cell-based therapeutic approaches (particularly immune checkpoint inhibitors). However, immune checkpoint inhibitors (ICIs) aren’t efficacious in all patients, and they carry risks. What are these risks? Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences speaks to Lu Rahman. Preclinical in vivo models serve as important… Read More

#Cancer Research #Exclusive Content #News

#AstraZeneca #Cancer research #Clinical trials #Institute of Cancer Research

First medicine approved in the EU to treat rare genetic condition

AstraZeneca and MSD’s Koselugo (selumetinib) has been granted conditional approval in the European Union for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. NF1 is a debilitating genetic condition affecting one in 3,000 individuals worldwide. In 30-50%… Read More

#News

#Cancer #Cancer research #Institute of Cancer Research #Life sciences

Work on new Innovation Gateway at The London Cancer Hub begins

The establishment of Innovation Gateway, a high-quality incubator space for life-science companies at The London Cancer Hub in Sutton, is underway. This is a significant step in realising the aims of The London Cancer Hub, a partnership between the London Borough of Sutton and The Institute of Cancer Research, that… Read More

#News

#Cancer research #Covid-19 #Institute of Cancer Research #Research

Funding cuts could capsize cancer research in the UK

Cancer research in the UK is at risk through a combination of proposed government funding cuts for UK science and the impact of the pandemic on charity funding, warns a leading cancer research institute. The Institute of Cancer Research (ICR) is revealing reductions of as much as a fifth in… Read More

#Cancer Research #News

#Cancer research #Drug development #Institute of Cancer Research #Oncology #Therapeutics

Resistance-busting ICR drug enters clinical trial

The Institute of Cancer Research (ICR), London, has discovered a drug that could counteract drug resistance in patients with cancers including acute myeloid leukaemia. It has entered a Phase I clinical trial at The Royal Marsden NHS Foundation Trust. The drug, now called EP0042, is a dual inhibitor of cancer-driving… Read More

#Cancer Research #Editor's Choice #News

#Institute of Cancer Research #Oncology #Precision medicine

Combining precision medicines can treat drug-resistant cancers

Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows. It is the first trial to use the pioneering genetically targeted drug olaparib – already licensed for ovarian, breast and prostate cancer – together… Read More

#Trending News